Commodore Capital’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $94.7M | Buy |
3,025,000
+700,000
| +30% | +$21.9M | 6.68% | 3 |
|
|
2025
Q1 | $78M | Sell |
2,325,000
-415,000
| -15% | -$13.9M | 5.75% | 5 |
|
|
2024
Q4 | $107M | Buy |
2,740,000
+40,000
| +1% | +$1.57M | 7.87% | 4 |
|
|
2024
Q3 | $106M | Sell |
2,700,000
-54,266
| -2% | -$2.14M | 6.64% | 3 |
|
|
2024
Q2 | $107M | Buy |
2,754,266
+586,473
| +27% | +$22.9M | 7.33% | 3 |
|
|
2024
Q1 | $93.3M | Hold |
2,167,793
| – | – | 6.24% | 4 |
|
|
2023
Q4 | $99.8M | Buy |
2,167,793
+322,793
| +17% | +$14.9M | 8.72% | 2 |
|
|
2023
Q3 | $63M | Hold |
1,845,000
| – | – | 7.37% | 3 |
|
|
2023
Q2 | $71M | Hold |
1,845,000
| – | – | 7.98% | 4 |
|
|
2023
Q1 | $66M | Buy |
1,845,000
+185,889
| +11% | +$6.65M | 10.05% | 1 |
|
|
2022
Q4 | $65.4M | Buy |
1,659,111
+64,179
| +4% | +$2.53M | 9.86% | 1 |
|
|
2022
Q3 | $57.6M | Hold |
1,594,932
| – | – | 9.26% | 2 |
|
|
2022
Q2 | $48.5M | Buy |
1,594,932
+392,319
| +33% | +$11.9M | 10.26% | 2 |
|
|
2022
Q1 | $36.8M | Buy |
1,202,613
+112,487
| +10% | +$3.44M | 8.21% | 5 |
|
|
2021
Q4 | $34.1M | Buy |
1,090,126
+510,694
| +88% | +$16M | 7.89% | 4 |
|
|
2021
Q3 | $8.85M | Buy |
579,432
+253,096
| +78% | +$3.87M | 2.33% | 17 |
|
|
2021
Q2 | $6.08M | Buy |
326,336
+24,944
| +8% | +$464K | 2.12% | 20 |
|
|
2021
Q1 | $5.4M | Sell |
301,392
-165,976
| -36% | -$2.97M | 2.15% | 21 |
|
|
2020
Q4 | $7.19M | Buy |
+467,368
| New | +$7.19M | 3.91% | 12 |
|